{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:12:29Z","timestamp":1785247949733,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Chongqing Science and Health Joint Medical Research Project","award":["2023MSXM072"],"award-info":[{"award-number":["2023MSXM072"]}]},{"name":"Dianjiang County Bureau of Science and Technology","award":["djkjxm2022shmskjcxyw006"],"award-info":[{"award-number":["djkjxm2022shmskjcxyw006"]}]},{"name":"Natural Science Foundation of Chongqing-Chongqing Science and Technology Development Foundation","award":["CSTB2024NSCQ- KJFZMSX0035"],"award-info":[{"award-number":["CSTB2024NSCQ- KJFZMSX0035"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04227-5","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:17:19Z","timestamp":1762953439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of low-molecular-weight heparin or rivaroxaban combined with immunotherapy and chemotherapy in the treatment of advanced nonsmall cell lung cancer: a prospective, randomized, controlled clinical study"],"prefix":"10.1007","volume":"74","author":[{"given":"Hongchuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"4227_CR1","doi-asserted-by":"publisher","first-page":"103417","DOI":"10.1016\/j.critrevonc.2021.103417","volume":"64","author":"J Kaur","year":"2021","unstructured":"Kaur J, Elms J, Munn AL, Good D, Wei MQ (2021) Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy. Crit Rev Oncol Hematol 64:103417","journal-title":"Crit Rev Oncol Hematol"},{"key":"4227_CR2","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7\u201333","journal-title":"CA Cancer J Clin"},{"key":"4227_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, Chen HD, Yu YW, Li N, Chen WQ (2021) Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 134:783\u2013791","journal-title":"Chin Med J (Engl)"},{"key":"4227_CR4","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/cac2.12197","volume":"41","author":"H Qiu","year":"2021","unstructured":"Qiu H, Cao S, Xu R (2021) Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond) 41:1037\u20131048","journal-title":"Cancer Commun (Lond)"},{"key":"4227_CR5","first-page":"217","volume":"24","author":"C Zhou","year":"2021","unstructured":"Zhou C, Wang J, Wang B et al (2021) Chinese experts consensus on immune checkpoint inhibitors for non-small cell lung cancer (2020 version). Zhongguo Fei Ai Za Zhi 24:217\u2013235","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"4227_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-24223-1_1","volume":"893","author":"LA Torre","year":"2016","unstructured":"Torre LA, Siegel RL, Jemal A (2016) Lung cancer statistics. Adv Exp Med Biol 893:1\u201319","journal-title":"Adv Exp Med Biol"},{"key":"4227_CR7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632\u2013634","journal-title":"J Thromb Haemost"},{"key":"4227_CR8","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.amjmed.2021.01.031","volume":"134","author":"AG Ording","year":"2021","unstructured":"Ording AG, Skj\u00f8th F, S\u00f8gaard M et al (2021) Increasing incidence and declining mortality after cancer-associated venous thromboembolism: a nationwide cohort study. Am J Med 134:868-876.e865","journal-title":"Am J Med"},{"key":"4227_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.thorsurg.2020.01.006","volume":"30","author":"J Judd","year":"2020","unstructured":"Judd J, Borghaei H (2020) Combining immunotherapy and chemotherapy for non-small cell lung cancer. Thorac Surg Clin 30:199\u2013206","journal-title":"Thorac Surg Clin"},{"key":"4227_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS et al (2024) Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 22:249\u2013274","journal-title":"J Natl Compr Cancer Netw"},{"key":"4227_CR11","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"P Chen","year":"2022","unstructured":"Chen P, Liu Y, Wen Y, Zhou C (2022) Non-small cell lung cancer in China. Cancer Commun 42:937\u2013970","journal-title":"Cancer Commun"},{"key":"4227_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay4860","author":"A Metelli","year":"2020","unstructured":"Metelli A, Wu BX, Riesenberg B et al (2020) Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-\u03b2. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aay4860","journal-title":"Sci Transl Med"},{"key":"4227_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaw8405","author":"C Graf","year":"2019","unstructured":"Graf C, Wilgenbus P, Pagel S et al (2019) Myeloid cell-synthesized coagulation factor X dampens antitumor immunity. Sci Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aaw8405","journal-title":"Sci Immunol"},{"issue":"Suppl 1","key":"4227_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1055\/s-2006-939555","volume":"32","author":"W Ruf","year":"2006","unstructured":"Ruf W, Mueller BM (2006) Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 32(Suppl 1):61\u201368","journal-title":"Semin Thromb Hemost"},{"key":"4227_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1182\/blood-2007-07-101048","volume":"111","author":"HH Versteeg","year":"2008","unstructured":"Versteeg HH, Schaffner F, Kerver M et al (2008) Inhibition of tissue factor signaling suppresses tumor growth. Blood 111:190\u2013199","journal-title":"Blood"},{"key":"4227_CR16","volume-title":"Guidelines of Chinese society of clinical oncology (CSCO) venous thromboembolism prophylaxis and treatment guideline in patients with cancer","author":"Guidelines Working Committee of the Chinese Society of Clinical Oncology","year":"2020","unstructured":"Guidelines Working Committee of the Chinese Society of Clinical Oncology (2020) Guidelines of Chinese society of clinical oncology (CSCO) venous thromboembolism prophylaxis and treatment guideline in patients with cancer. People\u2019s Health Publishing House, Beijing"},{"key":"4227_CR17","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.3390\/cancers13205103","volume":"13","author":"M Haist","year":"2021","unstructured":"Haist M, Stege H, Pemler S et al (2021) Anticoagulation with factor Xa inhibitors is associated with improved overall response and progression-free survival in patients with metastatic malignant melanoma receiving immune checkpoint inhibitors-a retrospective, real-world cohort study. Cancers (Basel) 13:5103","journal-title":"Cancers (Basel)"},{"key":"4227_CR18","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.21037\/apm-21-163","volume":"10","author":"P Li","year":"2021","unstructured":"Li P, Qin P, Fu X et al (2021) Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor. Ann Palliat Med 10:3039\u20133049","journal-title":"Ann Palliat Med"},{"key":"4227_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/cancers12010067","volume":"12","author":"F Nichetti","year":"2019","unstructured":"Nichetti F, Ligorio F, Zattarin E et al (2019) Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients. Cancers (Basel) 12:67","journal-title":"Cancers (Basel)"},{"key":"4227_CR20","first-page":"100","volume":"5","author":"National Health Commission of the People's Republic of China","year":"2019","unstructured":"National Health Commission of the People\u2019s Republic of China (2019) Diagnosis and treatment specifications for primary lung cancer (2018 Edition). Electron J Compr Cancer Treat 5:100\u2013120","journal-title":"Electron J Compr Cancer Treat"},{"issue":"1","key":"4227_CR21","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1186\/s12885-025-14246-1","volume":"25","author":"S Xu","year":"2025","unstructured":"Xu S, Chen Z, Chen X et al (2025) Interplay of disulfidptosis and the tumor microenvironment across cancers: implications for prognosis and therapeutic responses. BMC Cancer 25(1):1113","journal-title":"BMC Cancer"},{"key":"4227_CR22","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.2147\/JIR.S509245","volume":"18","author":"S Yang","year":"2025","unstructured":"Yang S, Liu H, Zheng Y et al (2025) The role of PLIN3 in prognosis and tumor-associated macrophage infiltration: a pan-cancer analysis. J Inflamm Res 18:3757\u20133777","journal-title":"J Inflamm Res"},{"issue":"1","key":"4227_CR23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/s12885-024-12182-0","volume":"24","author":"C Qiu","year":"2024","unstructured":"Qiu C, Wang W, Xu S et al (2024) Construction and validation of a hypoxia-related gene signature to predict the prognosis of breast cancer. BMC Cancer 24(1):402","journal-title":"BMC Cancer"},{"key":"4227_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","volume":"8","author":"AA Khorana","year":"2022","unstructured":"Khorana AA, Mackman N, Falanga A et al (2022) Cancer-associated venous thromboembolism. Nat Rev Dis Primers 8:11","journal-title":"Nat Rev Dis Primers"},{"key":"4227_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009565","author":"X Li","year":"2024","unstructured":"Li X, Gao L, Wang B et al (2024) FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-009565","journal-title":"J Immunother Cancer"},{"key":"4227_CR26","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","volume":"380","author":"AA Khorana","year":"2019","unstructured":"Khorana AA, Soff GA, Kakkar AK et al (2019) Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 380:720\u2013728","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"4227_CR27","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/S0049-3848(20)30406-0","volume":"191","author":"W Ruf","year":"2020","unstructured":"Ruf W, Graf C (2020) Coagulation signaling and cancer immunotherapy. Thromb Res 191(Suppl 1):S106-s111","journal-title":"Thromb Res"},{"issue":"83","key":"4227_CR28","doi-asserted-by":"publisher","first-page":"eabn6173","DOI":"10.1126\/sciimmunol.abn6173","volume":"8","author":"M van Gulijk","year":"2023","unstructured":"van Gulijk M, van Krimpen A, Schetters S et al (2023) PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Sci Immunol 8(83):eabn6173","journal-title":"Sci Immunol"},{"key":"4227_CR29","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/1097-0142(19840515)53:10<2046::AID-CNCR2820531007>3.0.CO;2-F","volume":"53","author":"LR Zacharski","year":"1984","unstructured":"Zacharski LR, Henderson WG, Rickles FR et al (1984) Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA cooperative study #75. Cancer 53:2046\u20132052","journal-title":"Cancer"},{"key":"4227_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12959-023-00453-y","volume":"21","author":"Y Song","year":"2023","unstructured":"Song Y, Yang D, Hou D, She J, Song Y (2023) Comparison of the efficacy and safety of rivaroxaban and low-molecular-weight heparin in Chinese lung cancer patients with nonhigh-risk pulmonary embolism. Thromb J 21:16","journal-title":"Thromb J"},{"key":"4227_CR31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","volume":"28","author":"J Zhu","year":"2010","unstructured":"Zhu J, Yamane H, Paul WE (2010) Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 28:445\u2013489","journal-title":"Annu Rev Immunol"},{"key":"4227_CR32","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","volume":"50","author":"JB Wing","year":"2019","unstructured":"Wing JB, Tanaka A, Sakaguchi S (2019) Human FOXP3(+) regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity 50:302\u2013316","journal-title":"Immunity"},{"key":"4227_CR33","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.immuni.2016.10.021","volume":"45","author":"M De Simone","year":"2016","unstructured":"De Simone M, Arrigoni A, Rossetti G et al (2016) Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity 45:1135\u20131147","journal-title":"Immunity"},{"key":"4227_CR34","doi-asserted-by":"publisher","first-page":"972021","DOI":"10.3389\/fimmu.2022.972021","volume":"13","author":"DS Kravtsov","year":"2022","unstructured":"Kravtsov DS, Erbe AK, Sondel PM, Rakhmilevich AL (2022) Roles of CD4 + T cells as mediators of antitumor immunity. Front Immunol 13:972021","journal-title":"Front Immunol"},{"key":"4227_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.it.2024.02.005","volume":"45","author":"M Guo","year":"2024","unstructured":"Guo M, Liu MYR, Brooks DG (2024) Regulation and impact of tumor-specific CD4(+) T cells in cancer and immunotherapy. Trends Immunol 45:303\u2013313","journal-title":"Trends Immunol"},{"issue":"39","key":"4227_CR36","doi-asserted-by":"publisher","first-page":"eaaw8405","DOI":"10.1126\/sciimmunol.aaw8405","volume":"4","author":"C Graf","year":"2019","unstructured":"Graf C, Wilgenbus P, Pagel S et al (2019) Myeloid cell-synthesized coagulation factor X dampens antitumor immunity. Sci Immunol 4(39):eaaw8405","journal-title":"Sci Immunol"},{"issue":"9","key":"4227_CR37","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1158\/1078-0432.CCR-23-1316","volume":"30","author":"A Mariniello","year":"2024","unstructured":"Mariniello A, Nasti TH, Chang DY et al (2024) Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade. Clin Cancer Res 30(9):1833\u20131845","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04227-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:45:24Z","timestamp":1764600324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04227-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4227"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04227-5","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Dianjiang County People\u2019s Hospital in Chongqing (20220912).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"371"}}